Recently, we have shown that IL-37 inhibits disease-related inflammatory cytokines in PBMCs of patients with systemic lupus erythematosus (SLE), Graves’ Disease(GD), ankylosing spondylitis (AS) and rheumatoid arthritis(RA)22–25. Here, IL37 is linked to systemic lupus erythematosus.